Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Non Small Cell Lung CancerLung Cancer
Interventions
DRUG

erlotinib

One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.

DRUG

Pemetrexed

pemetrexed 500 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.

DRUG

Cisplatin

cisplatin 75 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.

PROCEDURE

Resection

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER